Kidney transplantation from an ABO-incompatible (ABOi) living donor is a vital therapeutic option for addressing the severe shortage of solid organs. However, the presence in the recipient of natural (IgM) or immune (IgG) isohaemagglutinins (anti-A/anti-B) directed against ABO antigens expressed on the vascular endothelium of the transplant may cause acute (AMR) or hyperacute antibody-mediated rejection. To prevent such complications, clinical protocols (which combine targeted immunosuppressive therapies such as Rituximab and physical removal via plasmapheresis) require constant and accurate monitoring of antibody titres. At the Padua University Hospital, the immunological safety threshold for authorising access to transplantation has historically been set at a manual titre of 1:8. However, the introduction of new automated analytical platforms, characterised by different analytical sensitivity, raises a crucial question of clinical safety: a possible systematic bias in titres could lead to an analytical overestimation, resulting in unnecessary apheresis sessions or, conversely, a dangerous underestimation for the patient’s safety. At the Padua University Hospital, the immunological safety threshold for authorising access to transplantation has historically been set at a manual titre of 1:8. However, the introduction of new automated analytical platforms, characterised by differing levels of analytical sensitivity, raises a crucial clinical safety issue: any systematic deviation in titres could lead to an analytical overestimation, resulting in unnecessary apheresis sessions or, conversely, in an underestimation that could be dangerous for organ survival. The primary objective of this experimental study is the analytical validation and assessment of the clinical and operational impact of the new Grifols® automated immunohaematology analyser for the titration of anti-A and anti-B isohaemagglutinins. Specifically, the study aims to: assess the analytical agreement between manual testing using gel microcolumns and automated testing on the Grifols® platform; quantify the systematic deviation (bias) in IgM and IgG titres between the Grifols® method and the laboratory’s historical manual database (performed using Bio-Rad technology), defining accuracy within the limit of one dilution step; safely recalibrate the organisation’s clinical cut-off of 1:8 on the new equipment. To characterise the baseline distribution profile of immune isohaemagglutinins (IgG fraction) in a healthy control population.
Il trapianto di rene da donatore vivente ABO-incompatibile (ABOi) costituisce una risorsa terapeutica fondamentale per contrastare la grave carenza di organi solidi. Tuttavia, la presenza nel ricevente di isoemoagglutinine (anti-A/anti-B) naturali (IgM) o immuni (IgG) dirette contro gli antigeni ABO espressi sull'endotelio vascolare del trapianto può causare rigetti acuti (AMR) o iperacuti mediati da anticorpi. Per prevenire tali complicanze, i protocolli clinici (che combinano terapie immunosoppressive mirate come il Rituximab e la rimozione fisica tramite plasmaferesi) richiedono un monitoraggio costante e accurato dei titoli anticorpali. Presso l'Azienda Ospedale Università di Padova, la soglia di sicurezza immunologica per autorizzare l'accesso al trapianto è stabilita storicamente in un titolo manuale 1:8. L'introduzione di nuove piattaforme analitiche automatizzate, caratterizzate da una differente sensibilità analitica, solleva tuttavia un cruciale quesito di sicurezza clinica: un eventuale scarto sistematico nei titoli potrebbe portare a una sovrastima analitica, traducendosi in sessioni aferetiche superflue o, al contrario, in una sottostima pericolosa per la so Presso l'Azienda Ospedale Università di Padova, la soglia di sicurezza immunologica per autorizzare l'accesso al trapianto è stabilita storicamente in un titolo manuale 1:8. L'introduzione di nuove piattaforme analitiche automatizzate, caratterizzate da una differente sensibilità analitica, solleva tuttavia un cruciale quesito di sicurezza clinica: un eventuale scarto sistematico nei titoli potrebbe portare a una sovrastima analitica, traducendosi in sessioni aferetiche superflue o, al contrario, in una sottostima pericolosa per la sopravvivenza dell'organo. L’obiettivo primario di questo studio sperimentale è la validazione analitica e la valutazione dell'impatto clinico-operativo del nuovo analizzatore automatico immunoematologico Grifols® per la titolazione delle isoemoagglutinine anti-A e anti-B. Nello specifico, lo studio si propone di: valutare la concordanza analitica tra l'esecuzione manuale in microcolonna di gel e l'esecuzione automatizzata sulla piattaforma Grifols®; quantificare lo scarto sistematico (bias) dei titoli di IgM e IgG tra la metodica Grifols® e lo storico database manuale del laboratorio (eseguito con tecnologia Bio-Rad), definendo l'accuratezza entro il limite di 1 stadio di diluizione; ricalibrare in sicurezza il cut-off clinico aziendale 1:8 sulla nuova strumentazione. Caratterizzare il profilo distributivo basale delle isoemoagglutinine immuni (frazione IgG) in una popolazione di controllo sana.
Determinazione delle isoemoagglutinine anti-A e anti-B in candidati a trapianto renale da donatore vivente ABO incompatibile: confronto tra metodica manuale ed automatizzata
CALÒ, VALENTINA
2025/2026
Abstract
Kidney transplantation from an ABO-incompatible (ABOi) living donor is a vital therapeutic option for addressing the severe shortage of solid organs. However, the presence in the recipient of natural (IgM) or immune (IgG) isohaemagglutinins (anti-A/anti-B) directed against ABO antigens expressed on the vascular endothelium of the transplant may cause acute (AMR) or hyperacute antibody-mediated rejection. To prevent such complications, clinical protocols (which combine targeted immunosuppressive therapies such as Rituximab and physical removal via plasmapheresis) require constant and accurate monitoring of antibody titres. At the Padua University Hospital, the immunological safety threshold for authorising access to transplantation has historically been set at a manual titre of 1:8. However, the introduction of new automated analytical platforms, characterised by different analytical sensitivity, raises a crucial question of clinical safety: a possible systematic bias in titres could lead to an analytical overestimation, resulting in unnecessary apheresis sessions or, conversely, a dangerous underestimation for the patient’s safety. At the Padua University Hospital, the immunological safety threshold for authorising access to transplantation has historically been set at a manual titre of 1:8. However, the introduction of new automated analytical platforms, characterised by differing levels of analytical sensitivity, raises a crucial clinical safety issue: any systematic deviation in titres could lead to an analytical overestimation, resulting in unnecessary apheresis sessions or, conversely, in an underestimation that could be dangerous for organ survival. The primary objective of this experimental study is the analytical validation and assessment of the clinical and operational impact of the new Grifols® automated immunohaematology analyser for the titration of anti-A and anti-B isohaemagglutinins. Specifically, the study aims to: assess the analytical agreement between manual testing using gel microcolumns and automated testing on the Grifols® platform; quantify the systematic deviation (bias) in IgM and IgG titres between the Grifols® method and the laboratory’s historical manual database (performed using Bio-Rad technology), defining accuracy within the limit of one dilution step; safely recalibrate the organisation’s clinical cut-off of 1:8 on the new equipment. To characterise the baseline distribution profile of immune isohaemagglutinins (IgG fraction) in a healthy control population.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tesi Valentina Calò.pdf
Accesso riservato
Dimensione
896.95 kB
Formato
Adobe PDF
|
896.95 kB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119251